This website provides a curated collection of resources about the people, places and technologies that have enabled biotechnology to transform our healthcare and the world we live in today

Timeline of key events

immunotherapy: Timeline of key events

To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

Date Event People Places Sciences
Nov 1996Experiments demostrate antigen-specific CD4+ and T cells become tolerant during tumour growth in test tubes  Immunology, Immunotherapy, Oncology
1997FDA approved the first monoclonal antibody cancer drug for the American marketLevy, RastetterStanford University Medical School, Idec PharmaceuticalsImmunotherapy, Monoclonal antibodies
2000First clinical trials launched to test first immune checkpoint inhibitor drug containing a monoclonal antibody against CTLA-4 (ipilimumab, Yervoy®)AllisonMedarex, University of California BerkleyImmune checkpoint inhibitors, Immunology, Immunotherapy, Oncology, Monoclonal antibodies
14 Sep 2002Regulatory T cells discovered to restrain cytolytic T cells attacking cancer via messanger chemical called TGF-betaHerlyn, SomasundaramWistar InstituteImmunology, Immunotherapy, Oncology
17 Sep 2002Cancer cells shown to be capable of hijacking PD-1 protein to evade destruction by immune systemIwai , Ishida, Tanaka, Okazaki, Honjo, MinatoJapan Science and Technology CorporationImmune checkpoint inhibitors, Immunotherapy, Oncology
2003Genetic switch identified that controls the development of T cells, an important immune cell that controls against autoimmunity and excess inflammationFontenot, Gavin, RudenskyHoward Hughes Medical Institute, University of WashingtonImmunology, Immunotherapy
25 Mar 2011First immune checkpoint inhibitor drug targeting CTLA4 (ipilimumab, Yervoy®), approved by the FDAAlisonMedarex, University of California BerkleyImmune checkpoint inhibitors, Immunotherapy, Oncology, Monoclonal antibodies
22 Dec 2014First immune checkpoint inhibitor drug targeting PD-1 (nivolumab, Opdivo®) approved in US AlisonMedarex, Bristol-Myers Squibb, University of California BerkleyImmune checkpoint inhibitors, Immunotherapy, Oncology, Monoclonal antibodies
05 Jun 2015Two immunotherapy drugs reported to stop cancer cells avoiding destruction by immune system   Immunotherapy, Oncology, Monoclonal antibodies
27 Aug 2015Experiments with mice showed that azacytidine treatment enhanced the responsiveness of tumors to anti–CTLA-4 therapy  Cancer immunotherapy, Epigenetics, Immune checkpoint inhibitors, Oncology
25 Mar 2016Common tags discovered on the surface of cancer cells opening up new avenues for immunotherapyMcGranahan, Furness, Rosenthal, Ramskov, Lyngaa, Saini, Jamal-Hanjani, Wilson, Birkbak, Hiley, Watkins, Shafi, Murugaesu, Mitter, Akarca, Linares, Marafioti, Henry, Van Allen, Miao, Schilling, Schadendorf, Garraway, Makarov, Rizvi,m Snyder, Hellman, MerghUniversity College London, Cancer Research UK, Francis Crick Insitute, Dana-Farber Cancer Institute, Broad Institute, University Duisburg-Essen, Memorial Sloan Kettering Cancer Center, Columbia Univertsity, Weill Cornell Medical College, Harvard Medical SImmunology, Immunotherapy, Oncology
15 Apr 2016Gene editing used to prompt immune cells to combat cancerQuezada, Johnson, Menger, Sledzinska, Bergerhoff, Vargas, Smith, Poirot, Pule, Hererro, PeggsUniversity College London, Cancer Research UK, CellectisImmunology, Oncology, TALENs, Gene editing, Immunotherapy
21 Jun 2016US NIH Recombinant DNA Advisory Committee approved first study in 15 patients using CRISPR/Cas 9 to genetically modify immune cells to attack cancerJuneUniversity of PennsylvaniaCRISPR, Gene editing, Gene therapy, Immunotherapy
Aug 2016Marker identified for myeloid-derived suppressor cells, a type of cell associated with tumour resistance to certain cancer treatments Wistar InstituteImmunology, Immunotherapy, Oncology
24 Oct 2016FDA approved pembrolizumab (Keytruda®) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test. MerckImmune checkpoint inhibitors, Immunotherapy, Oncology, Monoclonal antibodies
23 Mar 2017US FDA granted accelerated approval to avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinomaEMD SeronoImmune checkpoint inhibitors, Immunotherapy, Oncology, Monoclonal antibodies

Website design by Silico Research the creative minds behind BioPartnering.

Follow us to keep up with all the new content about the world of biotechnology.